Back to Journals » Research Reports in Clinical Cardiology » Volume 6

P2Y12 inhibitors for acute coronary syndromes: current perspectives

Authors Nawarskas J, Newsome C, Anderson J, Ahmed B

Received 22 April 2015

Accepted for publication 26 May 2015

Published 9 October 2015 Volume 2015:6 Pages 123—143

DOI https://doi.org/10.2147/RRCC.S69478

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Richard Kones


James J Nawarskas,1 Cheyenne Newsome,2 Joe R Anderson,1 Bina Ahmed3

1Department of Pharmacy Practice and Pharmacy Administration, The University of New Mexico College of Pharmacy, 2Department of Pharmacy, The University of New Mexico Hospitals, 3Department of Internal Medicine, The University of New Mexico School of Medicine, The University of New Mexico, Albuquerque, NM, USA

Abstract: Antiplatelet therapies are a cornerstone for the management of acute coronary syndromes (ACSs), based largely on the prominent role that platelet activation and aggregation has on the pathophysiology of the disease. Dual-antiplatelet therapy involving an oral P2Y12 inhibitor plus aspirin is now considered standard of care for treating ACS. While clopidogrel has enjoyed nearly exclusive use as the P2Y12 inhibitor of choice for many years, the more powerful P2Y12 inhibitors prasugrel and ticagrelor have recently challenged clopidogrel as the preferred antiplatelet therapy for treating ACS. Both prasugrel and ticagrelor have proven to be superior to clopidogrel in reducing cardiovascular events in large clinical trials, albeit at the risk of increased bleeding. With the availability of these newer more potent agents, tailoring P2Y12 inhibition to be more patient specific becomes an intriguing possibility. Factors such as type of ACS presentation, patient comorbidities, use of concomitant medications, platelet reactivity, genetic predisposition, and cost should all be considered. In addition to oral agents, intravenous P2Y12 inhibition with cangrelor offers the advantage of quick onset and offset of action, but its clinical role is yet to be defined. Optimal medical and mechanical treatment of ACS hinges on suppressing platelet-related pathways, and P2Y12 inhibition plays a key role. As our understanding of ACS continues to evolve, there remains much to learn with respect to optimizing the use of these powerful drugs to most effectively help achieve the best clinical outcomes.

Keywords: P2Y12 inhibitors, acute coronary syndrome, ticagrelor, prasugrel, clopidogrel

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]